723. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [70675/26]

Summary

723. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [70675/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 6 October 2026

   Medicinal Products

   723. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [70675/26]

   Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 6 October 2026

  ViewDownloadOpen at official source

Sponsors

• Seán Kyne · Asking member
• Health · Health · Addressed to

Related records

No cross-record relationships stored yet.